Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Zacks Investment Research to Sell

Intra-Cellular Therapies} stock has undergone multiple analysts rating changes in the recent past.  Intra-Cellular Therapies Downgraded by Zacks Investment Research on 10/20/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Zacks Investment Research to Sell